In addition, higher PD-L1 and PD-L2 mRNA expression were associated with better OS to atezolizumab (anti PD-L1) in melanoma, RCC, NSCLC, and metastatic urothelial (Schmid et al., 2016; Yearley et al., 2017). Here, PDCD1LG2 is linked to non-small cell lung carcinoma.